



April 14, 2025

Dear WHO Expert Committee,

On behalf of World Child Cancer a non-governmental organization dedicated to improving childhood cancer care in low- and middle-income countries, we are writing to express our strong support for the inclusion of **blinatumomab** on the WHO Model List of Essential Medicines for Children.

Blinatumomab has proven efficacy in treating children with relapsed or refractory B-ALL and has the potential to reduce treatment-related toxicity compared to traditional chemotherapy. However, this life-saving treatment remains out of reach for many due to cost and availability.

We believe that listing blinatumomab on the EMLc would send a powerful signal to national governments, procurement agencies, and donors, enabling access through global platforms and encouraging health system readiness.

Thank you for your consideration of this vital application.

Sincerely,

Dana Bryson
Board Chair, World Child Cancer USA
USA

Patrick Weinberg
Board Treasurer, World Child Cancer USA
USA

The mission of World Child Cancer USA is to improve cancer diagnosis, treatment and care for children, and their families, across low-middle income countries.

cancelchildcancer.org

1301 Arapahoe St, Suite 105 Golden CO 80401

World Child Cancer USA is a registered 501(c)(3) nonprofit organization

USA Tax Identification Number: 46-0886328